At the Panagora Clinical Trial Innovation Summit 2025 in Basel, industry leaders highlighted the challenges facing Europe’s clinical trial ecosystem, including high costs, regulatory complexities, and competition from rapidly innovating Chinese biotech firms. Although Europe implemented new regulations in 2022, concerns about its attractiveness for clinical research persist. The need for efficient decentralized clinical trials (DCTs) was emphasized, with calls for better regulatory engagement and workforce development. Panelists noted that legacy IT systems hinder AI adoption in clinical trials and underlined the importance of proactive dialogue with regulators to streamline processes and improve outcomes. The forthcoming Biotech Act will serve as a critical test of the continent’s ability to modernize its clinical research landscape.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.clinicaltrialvanguard.com/conference-coverage/eu-clinical-trials-face-cost-speed-and-china-competition-pressure/
